Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice

Journal of Neurochemistry

Volumn 123, Issue 6, 2012, Pages 982-996

  Fournet, Vincent ^a   De Lavilléon, Gaetan ^a   Schweitzer, Annie ^a   Giros, Bruno ^a   Andrieux, Annie ^a   Martres, Marie Pascale ^a  

^a INSERM   (France)

Author keywords

antidepressant; anxiety depression; corticosterone; microtubule stabilizing compound; serotonin norepinephrine transporters; stress

Indexed keywords

CORTICOSTERONE; EPOTHILONE D; FLUOXETINE; MICROTUBULE PROTEIN; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; STABLE TUBULE ONLY POLYPEPTIDE; UNCLASSIFIED DRUG;

ACUTE STRESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL TEST; FLUID INTAKE; FORCED SWIMMING TEST; GROOMING; KNOCKOUT MOUSE; LIGHT DARK BOX TEST; MALE; MENTAL TASK; MOOD CHANGE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RECOGNITION; SCHIZOAFFECTIVE PSYCHOSIS; SHORT TERM MEMORY; TAIL SUSPENSION TEST; TASK PERFORMANCE;

AFFECT; ANIMALS; ANTINEOPLASTIC AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; EPOTHILONES; FEMALE; FLUOXETINE; MALE; MEMORY, SHORT-TERM; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; SEROTONIN UPTAKE INHIBITORS;

MUS;

EID: 84870587863     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12027     Document Type: Article

References (67)

1. Andrieux A., Salin P. A., Vernet M., et al,. (2002) The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev. 16, 2350-2364.
2. Andrieux A., Salin P., Schweitzer A., et al,. (2006) Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol. Psychiatry 60, 1224-1230.
3. Austin M. P., Mitchell P., and, Goodwin G. M., (2001) Cognitive deficits in depression: possible implications for functional neuropathology. Br. J. Psychiatry 178, 200-206.
4. Barten D. M., Fanara P., Andorfer C., et al,. (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in Tau transgenic mice with low doses of microtubule-stabilizing agent BMS-241027. J. Neurosci. 32, 7137-7145.
5. Begou M., Brun P., Bertrand J. B., Job D., Schweitzer A., D'Amato T., Saoud M., Andrieux A., and, Suaud-Chagny M. F., (2007) Post-pubertal emergence of alterations in locomotor activity in stop null mice. Synapse 61, 689-697.
6. Benmansour S., Owens W. A., Cecchi M., Morilak D. A., and, Frazer A., (2002) Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 22, 6766-6772.
7. Benson M. A., Sillitoe R. V., and, Blake D. J., (2004) Schizophrenia genetics: dysbindin under the microscope. Trends Neurosci. 27, 516-519.
8. Bianchi M., Shah A. J., Fone K. C., Atkins A. R., Dawson L. A., Heidbreder C. A., Hows M. E., Hagan J. J., and, Marsden C. A., (2009) Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse 63, 359-364.
9. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., and, Bartesaghi R., (2010) Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 30, 8769-8779.
10. Blackwood D., Pickard B., Thomson P., Evans K., Porteous D., and, Muir W., (2007) Are some genetic risk factors common to schizophrenia, bipolar disorder and depression ? Evidence from DISC1, GRIK4 and NRG1. Neurotox. Res. 11, 73-83.
11. Blier P., and, de Montigny C., (1994) Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15, 220-226.
12. Bouvrais-Veret C., Weiss S., Andrieux A., Schweitzer A., McIntosh J. M., Job D., Giros B., and, Martres M. P., (2007) Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology 52, 1691-1700.
13. Bouvrais-Veret C., Weiss S., Hanoun N., Andrieux A., Schweitzer A., Job D., Hamon M., Giros B., and, Martres M. P., (2008) Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission. J. Neurochem. 104, 745-756.
14. Brun P., Begou M., Andrieux A., Mouly-Badina L., Clerget M., Schweitzer A., Scarna H., Renaud B., Job D., and, Suaud-Chagny M. F., (2005) Dopaminergic transmission in STOP null mice. J. Neurochem. 94, 63-73.
15. Brunden K. R., Zhang B., Carroll J., et al,. (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J. Neurosci. 30, 13861-13866.
16. Chubb J. E., Bradshaw N. J., Soares D. C., Porteous D. J., and, Millar J. K., (2008) The DISC locus in psychiatric illness. Mol. Psychiatry 13, 36-64.
17. Delotterie D., Ruiz G., Brocard J., Schweitzer A., Roucard C., Roche Y., Suaud-Chagny M. F., Bressand K., and, Andrieux A., (2010) Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology 208, 131-141.
18. Domschke K., Lawford B., Young R., Voisey J., Morris C. P., Roehrs T., Hohoff C., Birosova E., Arolt V., and, Baune B. T., (2011) Dysbindin (DTNBP1)-a role in psychotic depression? J. Psychiatr. Res. 45, 588-595.
19. Eaton W. W., Martins S. S., Nestadt G., Bienvenu O. J., Clarke D., and, Alexandre P., (2008) The burden of mental disorders. Epidemiol. Rev. 30, 1-14.
20. Farley S., Dumas S., El Mestikawy S., and, Giros B., (2012) Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology 62, 503-517.
21. Fournet V., Jany M., Fabre V., et al,. (2010) The deletion of the microtubule-associated STOP protein affects the serotonergic mouse brain network. J. Neurochem. 115, 1579-1594.
22. Fournet V., Schweitzer A., Chevarin C., Deloulme J. C., Hamon M., Giros B., Andrieux A., and, Martres M. P., (2012) The deletion of STOP/MAP6 protein in mice triggers highly altered mood and impaired cognitive performances. J. Neurochem. 121, 99-114.
23. Fradley R. L., O'Meara G. F., Newman R. J., Andrieux A., Job D., and, Reynolds D. S., (2005) STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163, 257-264.
24. Frankle W. G., Lerma J., and, Laruelle M., (2003) The synaptic hypothesis of schizophrenia. Neuron 39, 205-216.
25. Gallassi R., Di Sarro R., Morreale A., and, Amore M., (2006) Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J. Affect. Disord. 91, 243-250.
26. Gardiner J., Overall R., and, Marc J., (2011) The microtubule cytoskeleton acts as a key downstream effector of neurotransmitter signaling. Synapse 65, 249-256.
27. Herman J. P., Figueiredo H., Mueller N. K., Ulrich-Lai Y., Ostrander M. M., Choi D. C., and, Cullinan W. E., (2003) Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary- adrenocortical responsiveness. Front. Neuroendocrinol. 24, 151-180.
28. Hirano K., Seki T., Sakai N., Kato Y., Hashimoto H., Uchida S., and, Yamada S., (2005) Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Res. 1053, 154-161.
29. Horsfield S. A., Rosse R. B., Tomasino V., Schwartz B. L., Mastropaolo J., and, Deutsch S. I., (2002) Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. Int. J. Psychiatry Med. 32, 337-344.
30. Ishizuka K., Paek M., Kamiya A., and, Sawa A., (2006) A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol. Psychiatry 59, 1189-1197.
31. Kajitani K., Thorne M., Samson M., and, Robertson G. S., (2010) Nitric oxide synthase mediates the ability of darbepoetin alfa to improve the cognitive performance of STOP null mice. Neuropsychopharmacology 35, 1718-1728.
32. Kamiya A., Tomoda T., Chang J., et al,. (2006) DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Hum. Mol. Genet. 15, 3313-3323.
33. Keefe R. S., Bilder R. M., Davis S. M., et al,. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633-647.
34. Kilpinen H., Ylisaukko-Oja T., Hennah W., Palo O. M., Varilo T., Vanhala R., Nieminen-von Wendt T., von Wendt L., Paunio T., and, Peltonen L., (2008) Association of DISC1 with autism and Asperger syndrome. Mol. Psychiatry 13, 187-196.
35. Kolman A., (2004) Epothilone D (Kosan/Roche). Curr. Opin. Investig. Drugs 5, 657-667.
36. Lanfumey L., Mongeau R., Cohen-Salmon C., and, Hamon M., (2008) Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci. Biobehav. Rev. 32, 1174-1184.
37. Levkovitz Y., Caftori R., Avital A., and, Richter-Levin G., (2002) The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res. Bull. 58, 345-350.
38. Li W. L., Cai H. H., Wang B., Chen L., Zhou Q. G., Luo C. X., Liu N., Ding X. S., and, Zhu D. Y., (2009) Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J. Neurosci. Res. 87, 112-122.
39. Lopez A. D., Mathers C. D., Ezzati M., Jamison D. T., and, Murray C. J., (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747-1757.
40. Maier W., (2008) Common risk genes for affective and schizophrenic psychoses. Eur. Arch. Psychiatry Clin. Neurosci. 258 (Suppl 2), 37-40.
41. Mathers C. D., and, Loncar D., (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442.
42. Matsuoka Y., Jouroukhin Y., Gray A. J., et al,. (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325, 146-153.
43. McEwen B. S., (2003) Mood disorders and allostatic load. Biol. Psychiatry 54, 200-207.
44. Merenlender-Wagner A., Pikman R., Giladi E., Andrieux A., and, Gozes I., (2010) NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 31, 1368-1373.
45. Millan M. J., Dekeyne A., Papp M., La Rochelle C. D., MacSweeny C., Peglion J. L., and, Brocco M., (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 298, 581-591.
46. Millar J. K., Wilson-Annan J. C., Anderson S., et al,. (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9, 1415-1423.
47. Mirnics K., Middleton F. A., Lewis D. A., and, Levitt P., (2001) Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 24, 479-486.
48. Morris J., Kandpal G., Ma L., and, Austin C., (2003) DISC1(disrupted-in- schizophrenia 1) is a centrosome-assciated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss if interaction with mutation. Hum. Mol. Genet. 12, 1591-1608.
49. Mostert J. P., Koch M. W., Heerings M., Heersema D. J., and, De Keyser J., (2008) Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci. Ther. 14, 153-164.
50. Mowla A., Mosavinasab M., and, Pani A., (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol. 27, 67-70.
51. Mutlu O., Ulak G., Laugeray A., and, Belzung C., (2009) Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol. Biochem. Behav. 92, 82-87.
52. Nettles J. H., Li H., Cornett B., Krahn J. M., Snyder J. P., and, Downing K. H., (2004) The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 305, 866-869.
53. Norton N., Williams H. J., and, Owen M. J., (2006) An update on the genetics of schizophrenia. Curr. Opin. Psychiatry 19, 158-164.
54. Owen M. J., Craddock N., and, O'Donovan M. C., (2005) Schizophrenia: genes at last? Trends Genet. 21, 518-525.
55. Pineyro G., and, Blier P., (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51, 533-591.
56. Porsolt R. D., Bertin A., Blavet N., Deniel M., and, Jalfre M., (1979) Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol. 57, 201-210.
57. Porter R. J., Gallagher P., Thompson J. M., and, Young A. H., (2003) Neurocognitive impairment in drug-free patients with major depressive disorder. Br. J. Psychiatry 182, 214-220.
58. Powell K. J., Hori S. E., Leslie R., Andrieux A., Schellinck H., Thorne M., and, Robertson G. S., (2007) Cognitive impairments in the STOP null mouse model of schizophrenia. Behav. Neurosci. 121, 826-835.
59. Schloesser R. J., Huang J., Klein P. S., and, Manji H. K., (2008) Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33, 110-133.
60. Seeman P., Schwarz J., Chen, J.-F., et al,. (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60, 319-346.
61. Song L., Che W., Min-Wei W., Murakami Y., and, Matsumoto K., (2006) Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol. Biochem. Behav. 83, 186-193.
62. Straub R. E., Jiang Y., MacLean C. J., et al,. (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71, 337-348.
63. Talbot K., Cho D. S., Ong W. Y., Benson M. A., Han L. Y., Kazi H. A., Kamins J., Hahn C. G., Blake D. J., and, Arnold S. E., (2006) Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum. Mol. Genet. 15, 3041-3054.
64. Taya S., Shinoda T., Tsuboi D., et al,. (2007) DISC1 regulates the transport of the NUDEL/LIS1/14-3-3e complex through kinesin-1. J. Neurosci. 27, 15-26.
65. Weiland-Fiedler P., Erickson K., Waldeck T., Luckenbaugh D. A., Pike D., Bonne O., Charney D. S., and, Neumeister A., (2004) Evidence for continuing neuropsychological impairments in depression. J. Affect. Disord. 82, 253-258.
66. Yalcin I., Belzung C., and, Surget A., (2008) Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav. Brain Res. 193, 140-143.
67. Zhang B., Carroll J., Trojanowski J. Q., et al,. (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 3601-3611.